Composition having strains of lactobacillus fermentum

Abstract

The invention relates to a pharmaceutical and/or dietetic composition for increasing the impact of the immune defense of higher living beings, wherein bacteria of the species Lactobacillus fermentum from at least one of the strains K1-Lb1 or K1-Lb6 or K2-Lb4 or K6-Lb4 or K7-Lb1 or K8-Lb1 or K9-Lb6 are contained in order to control the adaptive and natural immune defense by means of T helper 1 and T helper 2 cells and/or bacteria of the species Lactobacillus fermentum from at least one of the strains K2-Lb6 or K11-Lb3 are contained in order to strengthen the native immune defense.

1 . Pharmaceutical and/or dietetic composition for strengthening the effect of the human immune defense, characterized in that, to strengthen the adaptive immune defence by means of T helper 1 and T helper 2 cells, bacteria
 of the genus  Lactobacillus fermentum  of at least one of the strains   K1-Lb1 or   K1-Lb6 or   K2-Lb4 or   K6-Lb4 or   K7-Lb1 or   K8-Lb1 or   K9-Lb3 and/or   of the genus  Lactobacillus plantarum  of the strain K4-Lb6 and/or, to strengthen the native immune defence, bacteria of the genus  Lactobacillus fermentum  of at least one of the strains   K2-Lb6 or   K11-Lb3   
       are contained. 
     
     
         2 . Composition according to  claim 1 , characterized in that each strain is contained in Kimere. 
     
     
         3 . Composition according to one of the preceding claims, characterized in that the strengthening of the adaptive immune defense is a shift from the T helper 2 to the T helper 1 reactions. 
     
     
         4 . Composition according to  claim 3 , characterized in that at least one of the strains
 K1-Lb1 or   K1-Lb6 or   K2-Lb4 or   K4-Lb6 or   K6-Lb4 or   K9-Lb3   
       is contained. 
     
     
         5 . Composition according to one of the preceding claims, characterized in that the strengthening of the adaptive immune defense is a shift from the T helper 1 to the T helper 2 responses. 
     
     
         6 . Composition according to one of the preceding claims, characterized in that the strengthening of the adaptive immune defense is an inhibition of inflammations. 
     
     
         7 . Composition according to  claim 5  or  6 , characterized in that at least one of the strains
 K6-Lb4 or 
 K7-Lb1 or 
 K8-Lb1 
 
       is contained. 
     
     
         8 . Composition according to one of the preceding claims, characterized in that the strengthening of the adaptive immune defense is an increased release of defensin (hBD) from intestinal cells. 
     
     
         9 . Composition according to  claim 8 , characterized in that at least one of the strains
 K2-Lb6 or   K11-Lb3   
       is contained. 
     
     
         10 . Composition according to one of the preceding claims, characterized in that the strains tolerate a 0.3% bile salt solution. 
     
     
         11 . Composition according to one of the preceding claims, characterized in that the strain K4-Lb6 tolerates a 3.0% bile salt solution. 
     
     
         12 . Composition according to one of the preceding claims, characterized in that at least 8% of the strains survive a pH of 3.0 for at least 3 h. 
     
     
         13 . Composition according to  claim 12 , characterized in that at least one of the strains K1-Lb1 or K1-Lb6 or
 K2-Lb4 or   K2-Lb6 or   K4-Lb6 or   K6-Lb4 or   K7-Lb1 or   K8-Lb1 or   K9-Lb3   
       is contained. 
     
     
         14 . Composition according to one of the preceding claims, characterized in that, to influence the concentration and composition of glycosidic compounds at the membrane or at the wall of a bacterium, and therefore to modulate the immune response of a host, at least one of the strains expresses
 a glycosyl transferase or   a sugar transferase or   an acyl transferase or   a lipoteichonic acid-exporting protein.   
     
     
         15 . Composition according to  claim 14 , charazterized in that, for at least one of the strains for glycosyl transferase, the sugar residue docking can be catalyzed by diacylglycerol synthesis (DAG). 
     
     
         16 . Composition according to  claim 14 , characterized in that, for at least one of the strains, the acyl transferase can be catalyzed by diacylglycerol synthesis (DAG). 
     
     
         17 . Composition according to one of the preceding claims, characterized in that for at least one of the strains, enzymes catalyse further sugar transfer for the synthesis of microbial peptidoglycans. 
     
     
         18 . Composition according to one of the preceding claims, characterized in that, in the case of at least one of the strains, the expulsion from the cytoplasm is mediated
 by a lipoteichonic acid synthesis and/or   by a peptidoglycan synthesis   
       as transporter. 
     
     
         19 . Method for examining the identity of the strains according to one of the preceding claims, characterized in that the effect-mediating genes have a strain-specific pattern of the suppressive subtractive hybridization (SSH). 
     
     
         20 . Method according to  claim 19 , characterzied in that the part of 
       SSH can be determined by pulse field gel electrophoresis. 
     
     
         21 . Use of the composition according to claim, for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for prophylactic treatment or reduction of the risk of manifestation or for therapy of
 eczema and/or 
 atopic dermatitis and/or 
 asthma and/or 
 rhinitis allergica or 
 other allergies and/or 
 tuberculosis and/or 
 colitis ulcerosa and/or 
 eosinophilic pneumonia and/or 
 other Th2-driven illnesses or complaints. 
 
     
     
         22 . Use of the composition according to claim, for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for prophylactic treatment or reduction of the risk of manifestation or for therapy of
 intestinal infections and/or 
 travel diarrhoea and/or 
 colds and/or 
 urogenital infections and/or 
 HIV-associated complications and complains and/or 
 candidiasis 
 
       or other complaints, infections or other illnesses the defence against which is Th1-mediated. 
     
     
         23 . Use of the composition according to claim, for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for prophylactic treatment or reduction of the risk of manifestation or for therapy of
 rheumatoid arthritis and/or 
 hashimoto thyreoiditis and/or 
 uveitis and/or 
 psoriasis and/or 
 type 1 diabetes and/or
 sjögren disease and/or. 
 
 coeliac disease and/or 
 systemic lupus erythematosus and/or 
 ankylosing spondylitis and/or 
 Crohn's disease and/or 
 inflammatory intestinal diseases and/or 
 sclerodera and/or 
 sarcoidosis and/or 
 multiple sclerosis and/or 
 vitiligo and/or 
 Grave's autoimmune thyroiditis and/or 
 endocrinous opthalmopathy and/or 
 myasthenia gravis and/or 
 osteoarthritis and/or 
 arteriosclerosis and therefore also 
 cardiac infarction and/or 
 peripheral arterial occlusive diseases and/or 
 cerebral infarction (stroke) and/or 
 metabolic syndrome and therefore also 
 adipositas and/or 
 hypertonia and/or 
 insulin resistance and/or 
 type 2 diabetes and/or 
 dyslipoproteinaemia, as well as 
 amyotrophic lateral sclerosis and/or 
 interstitial cystitis and/or 
 irritable bowel syndrome (IBS) 
 other T helper 1-driven complains and illnesses. 
 
     
     
         24 . Use of the composition according to  claim 6 , for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for the reduction or elimination of the effects
 of autoimmune diseases such as arthritis or dermatitis or 
 of allergies or 
 of illnesses with inflammatory components such as a metabolic 
 
       syndrome or arteriosclerosis or those complaints and illnesses with inflammatory component mentioned in  claim 23 . 
     
     
         25 . Use of the composition according to  claims 11 , for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for the prophylaxis and therapy or osteoporosis by acidification of the milieu and displacement of other microorganisms with the 
       consequence of better mineral and trace element resorption. 
     
     
         26 . Use of the composition according to  claims 11 , for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for supportive therapy in the case of liver failure and hepatic encephalopathy due to lower resorption of toxins. 
     
     
         27 . Use of the composition according to  claims 11 , for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for the reduction of complaints in the 
       case of
 obstipation and/or 
 irritable bowel syndrome (IBS) and/or 
 halitosis. 
 
     
     
         28 . Use of the composition according to  claims 11 , for
 Preparing a medication or   a food supplement or   a pharmaceutical preparation   
       for reduction of lactose intolerance by improving the lactose exploitation and lactose digestion. 
     
     
         29 . Use of the composition according to  claims 11 , for
 preparing a medication or   a food supplement or   a pharmaceutical preparation   
       and/or for therapy of vaginosis or vaginitis. 
     
     
         30 . Use of the composition according to  claims 11 , for
 preparing a medication or   a food supplement or   a pharmaceutical preparation and/or   
       for intensifying and accelerating the bile acid and cholesterol metabolism.